United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Technology Industry News Tanla Platforms Q1 FY26 results: Can AI-native platform and share buyback strengthen investor sentiment despite modest revenue growth? Tanla Platforms Q1 FY26 results show steady margins and AI-driven expansion plans. Can buyback and Southeast Asian growth sustain investor confidence? byPallavi MadhirajuJuly 24, 2025